✦ The Future BetsNarrow moat

Johnson & Johnson (JNJ) — the future bets

J&J wants double-digit growth by the end of the decade and is paying for the attempt with $1.36 of next year's earnings per share.

Johnson & Johnson's stated ambition is a path to double-digit growth by the end of the decade1. Its 2026 guidance calls for reported sales of about $101.1 billion, 7.3% growth at the midpoint2, which would be more than $100 billion in annual revenue for the first time in the company's 140-year history3. Getting from 7% to double digits requires things that are not yet in the numbers.

2026 adjusted EPS guidance midpoint ($)11.53Jan 202611.55Apr 202611.6815 Jul 202611.0429 Jul 2026J&J results releases and Form 8-K, 29 July 2026
Raised twice, then cut by the deals.

Four bets carry most of that hope. The first is new science bought early: in July 2026 J&J completed the $1 billion purchase of Firefly Bio, with a platform aimed at hard-to-treat solid tumours including KRAS-driven cancers, and took an option to acquire Sail Biomedicines, which develops CAR-T therapies made inside the patient's body, for $2.58 billion45. The second is the separation of orthopaedics as DePuy Synthes, which J&J expects to raise the growth rate and margins of what remains6. The third is more than $55 billion of United States investment over four years7. The fourth is the ambition itself, due for a fuller account at an Enterprise Business Review planned for 8 December 20268.

The bets have a price, and it is visible. The Firefly and Sail transactions cut 2026 adjusted EPS guidance by approximately $0.64, to a midpoint of $11.04, and are expected to reduce 2027 adjusted EPS by approximately $1.369. Guidance had been raised twice before that, to $11.68 in July10.

These are narrower bets than they sound. In vivo CAR-T and degrader antibody conjugates are early-stage science; a separation removes a slow business but does not create a fast one; factories protect supply and tariff standing rather than adding demand.

Two regulatory approvals in the first quarter of 2026 hint at the next leg. Icotyde, described by J&J as the first-and-only targeted oral peptide for plaque psoriasis, and Tecvayli plus Darzalex Faspro as early as second-line myeloma were both approved in the quarter11. These are not future bets in the sense of new platforms, but they extend existing franchises in ways that could matter more to 2030 growth than any acquisition.

Management changes also mark the period. Jennifer Taubert, who led Innovative Medicine as it grew to more than $60 billion of annual revenue, is retiring, and Tom Cavanaugh, previously head of North America for the segment, succeeded her from 1 September 202612.

Investors will get a closer look soon. The third-quarter results are due on 13 October 202613, and they will include the in-process research charge of about $1 billion for Firefly14, the first full view of the cost of these bets.

Stripped of currency, the 2026 plan now looks flat. After the July deals J&J guides adjusted operational EPS to $10.94 at the midpoint, growth of about 1.4% on 202515. The bets are being paid for with a year in which earnings per share barely move, on the promise that the sales growth they buy arrives later.

The bets are sensible and mostly defensive, with two scientific options attached. The number to watch is 2027 adjusted EPS guidance, due with fourth-quarter results in January 2027: growth after absorbing the $1.36 dilution would show the base business outrunning the cost of the bets.

Moat trajectory: Widening

New scientific options were added in July 2026 and the orthopaedics separation is under way.

The number that tests this moat
Reported
2026 adjusted EPS guidance midpoint
$11.04 (from $11.68 on 15 July 2026)

The cost of the bets in this year's earnings; 2027 guidance after the $1.36 dilution is the next test.

Source: Johnson & Johnson guidance update, 29 July 2026 ↗
✦ Future bets — beyond today's moat
✦ FUTURE BET 01
In Vivo CAR-T and the Sail Option
J&J is paying $785 million up front for the option to buy a company that makes CAR-T therapies inside the patient's body.
✦ FUTURE BET 02
DePuy Synthes on Its Own
J&J is separating a $9.3 billion business growing 1% a year to make the rest of its device business look like a growth company.
✦ FUTURE BET 03
Fifty-Five Billion Dollars of American Plants
J&J's $55 billion United States investment is as much a tariff shield as a growth plan.
✦ FUTURE BET 04
Double-Digit Growth by the End of the Decade
J&J has promised double-digit growth by 2030 from a business that has compounded at 6.7% for five years.
References
  1. ReportedJohnson & Johnson's stated ambition is a path to double-digit growth by the end of the decade.
    Johnson & Johnson first-quarter 2026 results release, Form 8-K exhibit 99.1. — Q1 2026 · publ. 14 April 2026 · source ↗
  2. ReportedIts 2026 guidance calls for reported sales of about $101.1 billion, 7.3% growth at the midpoint, which would be more than $100 billion in annual revenue for the first time in the company's 140-year history.
    Johnson & Johnson second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 15 July 2026 · source ↗
  3. ReportedIts 2026 guidance calls for reported sales of about $101.1 billion, 7.3% growth at the midpoint, which would be more than $100 billion in annual revenue for the first time in the company's 140-year history.
    Johnson & Johnson second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 15 July 2026 · source ↗
  4. ReportedThe first is new science bought early: in July 2026 J&J completed the $1 billion purchase of Firefly Bio, with a platform aimed at hard-to-treat solid tumours including KRAS-driven cancers, and took an option to acquire Sail Biomedicines, which develops CAR-T therapies made inside the patient's body, for $2.58 billion.
    Johnson & Johnson announcement completing the acquisition of Firefly Bio, Form 8-K exhibit 99.1. — July 2026 · publ. 29 July 2026 · source ↗
  5. ReportedThe first is new science bought early: in July 2026 J&J completed the $1 billion purchase of Firefly Bio, with a platform aimed at hard-to-treat solid tumours including KRAS-driven cancers, and took an option to acquire Sail Biomedicines, which develops CAR-T therapies made inside the patient's body, for $2.58 billion.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  6. ReportedThe second is the separation of orthopaedics as DePuy Synthes, which J&J expects to raise the growth rate and margins of what remains.
    Johnson & Johnson announcement of its intent to separate the Orthopaedics business (DePuy Synthes), Form 8-K exhibit 99.3. — October 2025 · publ. 14 October 2025 · source ↗
  7. ReportedThe third is more than $55 billion of United States investment over four years.
    MassDevice, Johnson & Johnson to invest $55B in U.S. operations. — March 2025 · publ. 21 March 2025 · source ↗
  8. ReportedThe fourth is the ambition itself, due for a fuller account at an Enterprise Business Review planned for 8 December 2026.
    Johnson & Johnson first-quarter 2026 results release, Form 8-K exhibit 99.1. — Q1 2026 · publ. 14 April 2026 · source ↗
  9. ReportedThe Firefly and Sail transactions cut 2026 adjusted EPS guidance by approximately $0.64, to a midpoint of $11.04, and are expected to reduce 2027 adjusted EPS by approximately $1.36.
    Johnson & Johnson Form 8-K of 29 July 2026 - updated 2026 guidance after the Firefly and Sail transactions, and the 2027 dilution. — July 2026 · publ. 29 July 2026 · source ↗
  10. ReportedGuidance had been raised twice before that, to $11.68 in July.
    Johnson & Johnson second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 15 July 2026 · source ↗
  11. ReportedIcotyde, described by J&J as the first-and-only targeted oral peptide for plaque psoriasis, and Tecvayli plus Darzalex Faspro as early as second-line myeloma were both approved in the quarter.
    Johnson & Johnson first-quarter 2026 results release, Form 8-K exhibit 99.1. — Q1 2026 · publ. 14 April 2026 · source ↗
  12. ReportedJennifer Taubert, who led Innovative Medicine as it grew to more than $60 billion of annual revenue, is retiring, and Tom Cavanaugh, previously head of North America for the segment, succeeded her from 1 September 2026.
    Johnson & Johnson announcement of the retirement of Jennifer Taubert and appointment of Tom Cavanaugh, Form 8-K exhibit 99.1. — August 2026 · publ. 4 August 2026 · source ↗
  13. ReportedThe third-quarter results are due on 13 October 2026, and they will include the in-process research charge of about $1 billion for Firefly, the first full view of the cost of these bets.
    Johnson & Johnson (JNJ) market data - $270.57 a share on 24 September 2026, market cap $652.05B, dividend $5.36 (1.98%), 52-week range 175.74-281.07. — September 2026 · publ. 24 September 2026 · source ↗
  14. ReportedThe third-quarter results are due on 13 October 2026, and they will include the in-process research charge of about $1 billion for Firefly, the first full view of the cost of these bets.
    Johnson & Johnson announcement completing the acquisition of Firefly Bio, Form 8-K exhibit 99.1. — July 2026 · publ. 29 July 2026 · source ↗
  15. ReportedAfter the July deals J&J guides adjusted operational EPS to $10.94 at the midpoint, growth of about 1.4% on 2025.
    Johnson & Johnson Form 8-K of 29 July 2026 - updated 2026 guidance after the Firefly and Sail transactions, and the 2027 dilution. — July 2026 · publ. 29 July 2026 · source ↗
Sources
Generated September 24, 2026